Home News Glutamyl Aminopeptidase Market (EAP or Aminopeptidase A or Differentiation Antigen gp160 or...

Glutamyl Aminopeptidase Market (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Pipeline Review H2 2017

63
0
SHARE

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Glutamyl Aminopeptidase – Pipeline Review, H2 2017, outlays comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) – Glutamyl aminopeptidase is an enzyme encoded by the ENPEP gene. It is a zinc-dependent membrane-bound aminopeptidase that catalyzes the cleavage of glutamatic and aspartatic amino acid residues from the N-terminus of polypeptides. The enzyme degrades vasoconstricting angiotensin II into angiotensin III and helps to regulate blood pressure. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Report covers products from therapy areas Cardiovascular, Oncology and Women’s Health which include indications Hypertension, Congestive Heart Failure (Heart Failure), Endometriosis, Hepatic (Liver) Tumor, Idiopathic (Essential) Hypertension, Left Ventricular Dysfunction, Neuroblastoma and Resistant Hypertension.

Furthermore, this report also reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Complete research report is available at:

https://www.marketinsightsreports.com/reports/110233894/glutamyl-aminopeptidase-eap-or-aminopeptidase-a-or-differentiation-antigen-gp160-or-cd249-or-enpep-or-ec-3-4-11-7-pipeline-review-h2-2017

Companies Involved in Therapeutics Development are:

-APAvadis Biotechnologies Srl
-Quantum Genomics SA

Scope :

– The report provides a snapshot of the global therapeutic landscape for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
– The report reviews Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics and enlists all their major and minor projects
– The report assesses Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics

Reasons to buy:

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For Any queries feel free to reach us at: https://www.marketinsightsreports.com/reports/110233894/glutamyl-aminopeptidase-eap-or-aminopeptidase-a-or-differentiation-antigen-gp160-or-cd249-or-enpep-or-ec-3-4-11-7-pipeline-review-h2-2017/inquiry

About Us:

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more.

For more information contact at sales@marketinsightsreports.com or call us at +1 (704) 266-3234

Connect With us On : 

https://www.linkedin.com/company/13411016/

https://www.facebook.com/marketinsightsreports/

https://twitter.com/MIRresearch